IL265236B2 - Multipurpose medical buildings and their uses - Google Patents

Multipurpose medical buildings and their uses

Info

Publication number
IL265236B2
IL265236B2 IL265236A IL26523619A IL265236B2 IL 265236 B2 IL265236 B2 IL 265236B2 IL 265236 A IL265236 A IL 265236A IL 26523619 A IL26523619 A IL 26523619A IL 265236 B2 IL265236 B2 IL 265236B2
Authority
IL
Israel
Prior art keywords
toxin
peptide
peptides
seq
construct
Prior art date
Application number
IL265236A
Other languages
English (en)
Hebrew (he)
Other versions
IL265236B1 (en
IL265236A (en
Inventor
Morad Ilan
Itzhaki Hanan
Original Assignee
Aebi Ltd
Morad Ilan
Itzhaki Hanan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aebi Ltd, Morad Ilan, Itzhaki Hanan filed Critical Aebi Ltd
Publication of IL265236A publication Critical patent/IL265236A/en
Publication of IL265236B1 publication Critical patent/IL265236B1/en
Publication of IL265236B2 publication Critical patent/IL265236B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL265236A 2016-09-29 2017-09-27 Multipurpose medical buildings and their uses IL265236B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401192P 2016-09-29 2016-09-29
US201662401195P 2016-09-29 2016-09-29
PCT/IL2017/051094 WO2018061004A1 (en) 2016-09-29 2017-09-27 Therapeutic multi-targeting constructs and uses thereof

Publications (3)

Publication Number Publication Date
IL265236A IL265236A (en) 2019-05-30
IL265236B1 IL265236B1 (en) 2023-07-01
IL265236B2 true IL265236B2 (en) 2023-11-01

Family

ID=61763358

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265236A IL265236B2 (en) 2016-09-29 2017-09-27 Multipurpose medical buildings and their uses

Country Status (8)

Country Link
US (2) US11739163B2 (cg-RX-API-DMAC7.html)
EP (1) EP3518953A4 (cg-RX-API-DMAC7.html)
JP (1) JP7133225B2 (cg-RX-API-DMAC7.html)
CN (1) CN109789183A (cg-RX-API-DMAC7.html)
AU (2) AU2017333442A1 (cg-RX-API-DMAC7.html)
CA (1) CA3037261A1 (cg-RX-API-DMAC7.html)
IL (1) IL265236B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018061004A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) * 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
KR102268983B1 (ko) 2019-09-11 2021-06-24 경북대학교 산학협력단 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
CN112252362A (zh) * 2020-10-10 2021-01-22 无锡市市政设施建设工程有限公司 基于bim实现地铁车站主体结构盘扣支架搭设的方法
CN121494980A (zh) * 2025-12-12 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 抗胃泌素抗体及其杂交瘤细胞株和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064207A2 (en) * 2008-12-03 2010-06-10 Koji Kawakami Selective anticancer chimeric peptide
US20100151003A1 (en) * 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
WO2013126690A1 (en) * 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
WO2015195721A1 (en) * 2014-06-16 2015-12-23 Purdue Research Foundation Compositions and methods for treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058865A1 (en) 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
DK1915617T3 (da) 2005-07-21 2011-11-21 Aebi Ltd Fremgangsmåder og sammensætninger til identifikation af et peptid, der har en intermolekylær interaktion med et interessemål
US20100021473A1 (en) 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
ES2544954T3 (es) 2006-02-14 2015-09-07 Universita' Degli Studi Di Siena Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US8741839B2 (en) 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
US9321820B2 (en) 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Egfr結合性ペプチド
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
WO2015010094A1 (en) 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
US20200339629A1 (en) 2019-04-24 2020-10-29 Aebi Ltd. Therapeutic constructs comprising cmet binding peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151003A1 (en) * 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
WO2010064207A2 (en) * 2008-12-03 2010-06-10 Koji Kawakami Selective anticancer chimeric peptide
WO2013126690A1 (en) * 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
WO2015195721A1 (en) * 2014-06-16 2015-12-23 Purdue Research Foundation Compositions and methods for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANG, HAO-NAN, ET AL., BLOCKING OF THE PD?1/PD?L1 INTERACTION BY A D?PEPTIDE ANTAGONIST FOR CANCER IMMUNOTHERAPY. ANGEWANDTE CHEMIE INTERNATIONAL EDITION, 2015, 54.40: 11760-11764, 10 August 2015 (2015-08-10) *
KOHNO, MASAYUKI, ET AL., A NOVEL HYBRID PEPTIDE TARGETING EGFR-EXPRESSING CANCERS. EUROPEAN JOURNAL OF CANCER, 2011, 47.5: 773-783., 26 November 2010 (2010-11-26) *
MISHRA, PRAJNA; NAYAK, BISMITA; DEY, R. K., PEGYLATION IN ANTI-CANCER THERAPY: AN OVERVIEW. ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 11.3: 337-348, 14 September 2015 (2015-09-14) *
WU, DONGDONG, ET AL., PEPTIDE-BASED CANCER THERAPY: OPPORTUNITY AND CHALLENGE. CANCER LETTERS, 2014, 351.1: 13-22, 13 May 2014 (2014-05-13) *

Also Published As

Publication number Publication date
EP3518953A1 (en) 2019-08-07
AU2017333442A1 (en) 2019-04-04
JP2020501513A (ja) 2020-01-23
US20240002547A1 (en) 2024-01-04
AU2022221434A1 (en) 2022-10-06
US11739163B2 (en) 2023-08-29
EP3518953A4 (en) 2020-10-28
IL265236B1 (en) 2023-07-01
CN109789183A (zh) 2019-05-21
US20190225711A1 (en) 2019-07-25
CA3037261A1 (en) 2018-04-05
IL265236A (en) 2019-05-30
WO2018061004A1 (en) 2018-04-05
JP7133225B2 (ja) 2022-09-08

Similar Documents

Publication Publication Date Title
US8940863B2 (en) Selective anticancer chimeric peptides which bind neuropilin receptor
JP6722134B2 (ja) セリンプロテアーゼ分子および療法
IL265236B1 (en) Multipurpose medical buildings and their uses
CN103237808B (zh) 抗癌融合蛋白
US8618060B2 (en) Metallothionein-derived peptide fragments
CN103180339A (zh) 具有改善的稳定性的基于纤连蛋白的支架蛋白质
JP2012529272A (ja) Gdnfおよびbdnfを中枢神経系へ送達するための融合タンパク質
US9254309B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
JP2023145635A (ja) 免疫調節特性を有するペプチド
AU2016332062A1 (en) Treatment of bile acid disorders
KR102348838B1 (ko) 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
CN110799211B (zh) 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
JP2014525740A (ja) Cd47とトロンボスポンジンファミリーに属する蛋白質との結合に対するアンタゴニストペプチド
CN115666522B (zh) 包含il-2蛋白和cd80蛋白的融合蛋白制剂
CN117683140A (zh) 肿瘤靶向的以白介素2为活性成分的融合蛋白型药物前体
CN116761814A (zh) 多结构域融合蛋白及其应用
KR102726136B1 (ko) Pd-l1 결합 펩타이드 2를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
WO2019204402A1 (en) Compositions and methods for treatment of cancer
CN102154355A (zh) 一种重组免疫毒素ccl25-pe38基因及制备方法和应用
KR20090118626A (ko) 알지디-폴리에틸렌 글리콜이 수식된 트레일, 이의제조방법, 및 용도
KR101531944B1 (ko) Vegf에 특이적으로 결합하는 vegf-bpb
Class et al. Patent application title: Metallothionein-Derived Peptide Fragments Inventors: Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK) Milena Penkowa (Copenhagen V, DK) Assignees: UNIVERSITY OF TASMANIA